1. Patient Heterogeneity in CD

2. Individualized Predictive Markers for Severe CD

3. Tight Monitoring and Treat-to-Target Approach: CALM Trial

4. Biologic Therapy for CD

5. Anti-TNF: Mucosal Healing in CD

6. Ustekinumab: Mucosal Healing in CD

7. Vedolizumab: Endoscopic Healing and Remission in CD

8. VICTORY Consortium: Vedolizumab vs Anti-TNF Therapy (Propensity Score Matched Analysis)

9. Vedolizumab Safety Profile: Data From the GEMINI2 Trial

10. Ustekinumab Safety Profile: Data From the UNITI-2 Trial

11. Monitoring Patients: Beyond Clinical Symptoms

12. Abbreviations